Cell Stem Cell 17 (2):135-137 (2015)

Authors
Alex John London
Carnegie Mellon University
Danielle M. Wenner
Carnegie Mellon University
Abstract
Patient-funded trials are gaining traction as a means of accelerating clinical translation. However, such trials sidestep mechanisms that promote rigor, relevance, efficiency, and fairness. We recommend that funding bodies or research institutions establish mechanisms for merit review of patient-funded trials, and we offer some basic criteria for evaluating PFT protocols
Keywords No keywords specified (fix it)
Categories (categorize this paper)
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy

 PhilArchive page | Other versions
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Add more references

Citations of this work BETA

Donor-Funded Research: Permissible, Not Perfect.Mike King & Angela Ballantyne - 2019 - Journal of Medical Ethics 45 (1):36-40.

Add more citations

Similar books and articles

Clinical Trials--A Brave New Partnership?H. Thornton - 1994 - Journal of Medical Ethics 20 (1):19-25.
Palliative Care and Cancer Trials.S. M. Brown - 2003 - Journal of Medical Ethics 29 (6):371-371.

Analytics

Added to PP index
2015-10-16

Total views
279 ( #30,476 of 2,420,320 )

Recent downloads (6 months)
18 ( #41,309 of 2,420,320 )

How can I increase my downloads?

Downloads

My notes